Treatment of depression in diagnosed diabetes: common cause or detection bias?

K. Manderbacka¹*, M. Jokela², R. Sund¹ and M. Elovainio¹

¹National Institute for Health and Welfare, Service System Research Unit, Helsinki, Finland ²Institute of Behavioral Sciences, University of Helsinki, Finland

Background. This study examined two competing hypotheses concerning the association between diabetes and treatment for depression: (1) the detection/ascertainment bias hypothesis suggesting that those with diabetes are more likely to be diagnosed with and treated for depression because of increased medical attention and (2) a hypothesis assuming that diabetes and depression share common underlying pathophysiological pathways.

Method. The study population included all persons aged 35–65 years in Finland with any record of type 2 diabetes in the national health and population registers from 1999 to 2002 and for whom register-based data on depression treatment (antidepressant medication use and hospitalizations for depression) were available at least 2 years before and after the diagnosis of diabetes (n=18217). Sociodemographic data were individually linked to the study population. Associations between diabetes diagnosis and time and indicators of depression care were assessed with population-averaged multilevel logistic models.

Results. Within the year following diagnosis diabetes, there was a 5% increase in antidepressant medication use but not in hospitalization for depression. The longitudinal change in antidepressant use over time was less steep after the diabetes diagnosis, and hospitalization risk decreased after the diagnosis. These associations between diabetes diagnosis and depression treatment were not modified by the participant's socio-economic position (SEP).

Conclusions. These findings support the common cause hypothesis that treatment for diabetes is beneficial to the prevention of depression rather than the detection/ascertainment hypothesis that individuals with diabetes have higher rates of depression because they receive more medical attention in general.

Received 28 November 2012; Revised 29 May 2013; Accepted 29 May 2013; First published online 21 August 2013

Key words: Depression, diabetes, register-based study.

Introduction

The incidence of both type 1 and type 2 diabetes is increasing worldwide. Although there has been a large increase in type 1 diabetes (Onkamo *et al.* 1999; Harjutsalo *et al.* 2008), an epidemic expansion of type 2 diabetes has been considered to be the main contributor to the increase in European countries, including Finland (Passa 2002; Lammi *et al.* 2008). In addition to other complications, persons with diabetes suffer from higher rates of depression compared to the general population (Viinamaki *et al.* 1995; Hanninen *et al.* 1999; Talbot & Nouwen, 2000; Anderson *et al.* 2001; de Groot *et al.* 2011; Ali *et al.* 2006; Knol *et al.* 2006; Nouwen *et al.* 2010). The mechanisms responsible for this association remain unclear. Diabetes or its treatment may influence the risk for depression, depression or its treatment may influence diabetes, or the two may share common causes, such as metabolic disorders, obesity or lifestyle factors (Knol *et al.* 2006; Hamer *et al.* 2010; Kivimäki *et al.* 2010).

A study in The Netherlands found that antidepressant use was elevated 2 months before and 3 months after the diagnosis of diabetes, suggesting a short-term increase in depression associated with diabetes diagnosis (Knol et al. 2009). A similar pattern was observed in the Whitehall II study (Kivimaki et al. 2011), which also showed that antidepressant use was more common among individuals with diagnosed diabetes, although long-term use of antidepressants was not associated with subsequent risk of undiagnosed diabetes or higher plasma glucose levels. A study from the USA examining middle-aged persons in a primary healthcare setting found that persons with type 2 diabetes were more likely to be diagnosed with depression within 2 years from the diabetes diagnosis; however, if patients with or without diabetes made more than four primary care visits during the study period, the association disappeared (O'Connor et al. 2009).

^{*} Address for correspondence: K. Manderbacka, Ph.D., National Institute for Health and Welfare, Service System Research Unit, PO Box 30, 00271 Helsinki, Finland.

⁽Email: kristiina.manderbacka@thl.fi)

Given that patients diagnosed with diabetes are regularly in contact with primary health care, they may be more likely to be diagnosed and treated for other medical conditions, including depression (detection or ascertainment bias). Together these findings imply that the aspects of clinical diagnosis and medical treatment may be particularly important in characterizing the association between diabetes and depression in the general population.

Previous research on the socio-economic inequalities in medical treatment suggests that individuals with high socio-economic position (SEP) are treated more actively. High SEP has also been associated with better treatment among individuals with diabetes (Edwards *et al.* 2003; McWilliams *et al.* 2009; Wilf-Miron *et al.* 2010) and with higher prevalence of antidepressant use, even though mental health problems are more common among individuals with low SEP (Kivimaki *et al.* 2007). Thus, socio-economic differences can be used as a marker to further investigate the role of diagnosis-related associations between diabetes and depression; the diagnosis-related associations are expected to be stronger among individuals with high compared to low SEP.

The aim of this study was to examine the association between diabetes diagnosis and treatment of depression. Using longitudinal register-based data from diabetic individuals before and after the diagnosis of diabetes, we examined whether treatment for depression changes after versus before diabetes diagnosis and whether this change is dependent on SEP. We had two competing hypotheses. First, if the association between diabetes and depression is due to detection/ ascertainment bias, we would expect treatment for depression to increase after the diagnosis of diabetes in the short term (within 1 year of diagnosis) and in the long term (over the follow-up period). Furthermore, we would expect these changes to be larger among persons with higher SEP because they are likely to receive more active treatment. As an alternative to the ascertainment hypothesis, we considered the common cause hypothesis. Assuming that diabetes and depression share some common underlying pathophysiological pathways, such as poor glucose metabolism (Knol et al. 2006; Hamer et al. 2010), we could expect that the treatment of diabetes would also have a positive effect on depressive symptoms. If the common cause hypothesis is correct, we would find decreasing probability of treatment for depression after versus before the diagnosis of diabetes. Given that adherence to medical treatment is likely to be higher among individuals with higher SEP (DiMatteo, 2004; Wamala et al. 2007; Marcum et al. 2013), this change might also be stronger among individuals with high compared to low SEP because the treatment effects are expected to be more potent among the former.

Method

Data collection

Data on persons diagnosed with diabetes in Finland in 1996-2002 were obtained from the FinDM II database (Sund & Koski, 2009), which includes individuals with diabetes identified from: (1) the register of individuals eligible for elevated reimbursement of medication costs for chronic conditions including diabetes, (2) the prescription register including all reimbursed medicines purchased, (3) the national hospital discharge registers including all in-patient care and outpatient hospital visits, (4) the cause-of-death register, and (5) the medical birth register. Diabetes diagnosis was considered to be made if a person was on hypoglycemic medication or had been hospitalized for diabetes. Use of hypoglycemic medication is registered in the reimbursement register of the Social Insurance Institution, which is appointed special reimbursement rights for hypoglycemic medication costs (data from 1964 to 2007) and medication purchases registered (data from 1994 to 2007) with the Anatomical Therapeutic Chemical (ATC) classification code A10. Diabetes type was determined on the basis of prescription data. A comparison to a local diabetes register of the Helsinki metropolitan area has demonstrated good coverage of diabetic patients in the nationwide register (Sund et al. 2010).

Persons in permanent institutional care were excluded because SEP cannot be reliably ascribed to them from the registers used. Follow-up data containing indicators of depression and dates of death for the cohort were also obtained from the FinDM II database. Indicators for depression care included the purchase on antidepressants (ATC: N06A) in 1997-2007 and hospitalization with a main diagnosis of depression (ICD-10: F32-F33) in 1996-2007. Sociodemographic data on sex, age as a continuous variable and income were obtained from Statistics Finland. Data on income were extracted from the individual-level annual employment statistics compiled from several administrative registers. These were classified into quintiles according to family net income, and adjusted for family size according to the Organization for Economic Cooperation and Development (OECD) equivalence scale (OECD, 2012). The Finnish personal identity codes unique to each resident and used in all registers allowed deterministic record linkage within and between registers.

For the purposes of the current study, we focused on the patients with type 2 diabetes who were 35–65 years old at the time of diabetes diagnosis between 1999 and

	Model 1: Level	Model 2: Slope	Model 3: Level+Slope
Time (years)	1.04 (1.03–1.04)	1.09 (1.08–1.10)	1.08 (1.06–1.09)
Diabetes diagnosis	1.14 (1.10–1.18)	-	1.05 (1.01–1.10)
Time × diabetes diagnosis	-	0.95 (0.93–0.96)	0.96 (0.94–0.97)

Table 1. Use of antidepressant medication before and after diagnosis of diabetes

Values are odds ratios (and 95% confidence intervals) of logistic populationaveraged multilevel models (n=18217 participants, n=196884 person-year observations). All models are adjusted for sex, age at diabetes diagnosis, year of diabetes diagnosis, and years of follow-up after diabetes diagnosis. Time is centered at age at diabetes diagnosis. The diabetes diagnosis variable has the value 0 before diagnosis and 1 after diagnosis.

2002 (mean age=54.1 years, s.D.=7.1; 39% women). To provide a sufficient longitudinal setting, each patient also had to have register-based data on depression treatment available at least 2 years before and 2 years after the year of diabetes diagnosis to be included in the sample; for most included individuals the followup period was much longer than the 5 years required by this inclusion criteria (average follow-up time 10.8 years). The results were essentially the same when this exclusion criterion was not used (data not shown). The final sample included 18217 unique individuals contributing a total of 196884 person-observations over the follow-up period.

Statistical analysis

Associations between diabetes diagnosis, time and indicators of depression care (antidepressant medication use and hospitalization for depression) were assessed with population-averaged multilevel logistic models. Time was coded in years and centered for each participant so that time=0 at the year when the participant was diagnosed diabetes, time<0 before diagnosis and time ≥ 0 after diagnosis. One covariate (main effect of diabetes diagnosis) assessed whether there was an overall change in the level of depression before (time < 0) versus after (time ≥ 0) diabetes diagnosis. Another covariate assessing the difference in the trajectory of depression care over time was constructed as the interaction effect between diabetes diagnosis and time. Thus, the final model allowed depression care to change in level and time before versus after diabetes diagnosis. At each year a participant could receive antidepressant prescription or hospitalization for depression. These outcomes were examined in separate models. The role of socio-economic differences was assessed by including interaction effects between income and the three components of the depression care trajectory (main effect of time, main effect of diagnosis, and the interaction effect between the two). All models were further adjusted for sex, age at diabetes diagnosis and year at diabetes diagnosis. In addition, to adjust for the potential confounding effects of selective attrition over time (mostly due to deaths occurring after the diagnosis of diabetes), we applied the method of pattern mixture modeling (Hedeker & Gibbons, 1997) by including in all models a covariate that indicated the years of follow-up after the participant's diabetes diagnosis. The random-intercept logistic regression models were fitted using the xtlogit package of Stata release 12.1 (Stata Corporation, USA).

Results

Antidepressant medication use

The use of antidepressant medication was observed for 11.4% (22448/196884) of the person-year observations. In total, 28.2% (5139/18217) of the unique individuals in the sample had at least one antidepressant prescription during the follow-up period. When examining only the level of change before and after diabetes diagnosis, there was a 14% increase in the odds of using antidepressant medication (Table 1, model 1). However, there was also evidence for a changing slope over time associated with diabetes diagnosis (model 2), so both change in level and slope were included in the final model (model 3). Model 3 indicated a minor 5% increased odds in the overall level of antidepressant medication use after diabetes diagnosis but a less steeply increasing slope; before diagnosis, the odds of medication use increased by 1.08 per year [95% confidence interval (CI) 1.06-1.09] but after diagnosis this rate attenuated to 1.03 per year (95% CI 1.03–1.04, p<0.001 for difference between before versus after), as indicated by the interaction effect between time and diabetes diagnosis (slope after diabetes $diagnosis = 1.079 \times 0.957 = 1.03$).

We then examined whether there were socioeconomic differences in these change patterns by



Fig. 1. Risk of antidepressant medication before and after diabetes diagnosis by income level (low=lowest income quintile, high=highest income quintile).

including interaction effects of continuously coded income quintiles and all of the three components of model 3 (time, diabetes diagnosis, time × diabetes diagnosis). High income was associated with lower antidepressant medication use [odds ratio (OR) 0.87 per quintile, 95% CI 0.85–0.89] but did not modify the associations of diabetes diagnosis with level or slope of medication use before *versus* after diagnosis (all *p* values>0.18). The results of this model are illustrated in Fig. 1 for participants in the highest and lowest income quintiles.

Hospitalization for depression

Hospitalization for depression was observed for 0.4% (752/196884) of the person-year observations over the follow-up period. In total, 2.5% (458/18217) of the participants in the sample were hospitalized for depression at least once during the follow-up period. There was no change in overall level of hospitalization risk before *versus* after diabetes diagnosis after the change in slope over time was taken into account (Table 2). The interaction effect between diagnosis and time indicated that the risk of hospitalization remained constant over time before diabetes diagnosis (OR 1.07, 95% CI 0.98–1.17) but decreased with time after diagnosis (OR 0.94 per year, 95% CI 0.91–0.98, p=0.004 for difference in slope before *versus* after diagnosis).

Socio-economic differences in the risk of hospitalization in relation to time before and after diabetes diagnosis were tested for by including interaction effects with income level and time, diabetes diagnosis and time by diagnosis in model 3 (Table 2). High income was related to lower risk of hospitalization (OR 0.80 per income quintile, 95% CI 0.74–0.87) but did not modify associations with diabetes diagnosis (all p values >0.54). The parallel patterns for individuals with high *versus* low income are shown in Fig. 2.

Discussion

Previous studies of the association between diabetes and risk of depression have identified differential diagnosis and treatment patterns as potential explanatory factors for the association; depression may be identified more often in people who are diagnosed with diabetes. If, however, diabetes and depression share common physiological correlates, treatment for diabetes might also alleviate symptoms of depression. We used longitudinal register-based data on diabetes diagnosis, antidepressant treatment and hospitalizations due to depression among all Finnish individuals with type 2 diabetes to examine these patterns in more detail. Within the year following diabetes diagnosis, there was a minor increase in antidepressant medication use but not in hospitalization for depression. The longitudinal change in antidepressant use over time was less steep after the diabetes diagnosis, and hospitalization risk also decreased after the diagnosis. These associations between diabetes diagnosis and depression treatment were not modified by the participant's SEP. Together these findings support the common cause hypothesis (i.e. treatment for diabetes is

	Model 1: Level	Model 2: Slope	Model 3: Level+Slope
Time (years)	0.96 (0.92–1.00)	1.05 (0.99–1.11)	1.07 (0.97–1.17)
Diabetes diagnosis	1.13 (0.89–1.43)	-	0.93 (0.70-1.22)
Time × diabetes diagnosis	-	0.90 (0.83–0.97)	0.88 (0.80-0.98)

Table 2. Risk of hospitalization for depression before and after diagnosis of diabetes

Values are odds ratios (and 95% confidence intervals) of logistic populationaveraged multilevel models (n=18217 participants, n=196884 person-year observations). All models are adjusted for sex, age at diabetes diagnosis, year of diabetes diagnosis, and years of follow-up after diabetes diagnosis. Time is centered at age at diabetes diagnosis. The diabetes diagnosis variable has the value 0 before diagnosis and 1 after diagnosis.



Fig. 2. Risk of hospitalization for depression before and after diabetes diagnosis by income level (low=lowest income quintile, high=highest income quintile).

also beneficial to prevention of depression) rather than the detection/ascertainment hypothesis (i.e. diabetic individuals have higher rates of depression because they receive more medical attention in general).

Some previous studies have observed a transient increase in the use of antidepressants after the diagnosis of diabetes (Knol *et al.* 2009; Kivimaki *et al.* 2011). Consistent with these findings, we found a modest increase in the incidence of antidepressant use within the year following the diabetes diagnosis. The diagnosis of a chronic disease may adversely affect people's mental health, but people tend to adjust psychologically to their medical conditions. People going through the diagnosis of diabetes may be more likely to be diagnosed also with depression, as suggested by the detection/ascertainment bias hypothesis. However, there was no evidence of increased antidepressant medication use or hospitalization for depression after diabetes diagnosis over the long term; in fact the risk of antidepressant use increased more modestly and hospitalization for depression decreased more steeply after than before the diagnosis of diabetes. These patterns are in contrast to the detection/ascertainment bias hypothesis, but are in agreement with the hypothesis that treatment of diabetes has a beneficial effect on preventing future depression risk. Although our findings suggest that treatment of diabetes is accompanied by decreasing levels of depression risk, the present data do not allow us to identify what aspects of diabetes treatment might be responsible for these changes. In addition to the biological effects of diabetes medication, the adoption of healthier lifestyles (e.g. quitting smoking, increased exercise, better diet) after having been diagnosed with diabetes might decrease the later risk of depression among diabetic patients, as better health behaviors are associated with lower risk of depression.

Our study also included SEP as a potential moderator factor in the association between diabetes diagnosis and subsequent treatment for depression. Although there were considerable differences in the overall level of depression treatment between income groups (higher income being associated with lower probability of treatment), income did not moderate the short- or long-term patterns of depression treatment. High SEP is generally associated with receiving better medical care. The lack of effect moderation by SEP therefore provides indirect evidence against the hypothesis that depression would be more likely to be detected after than before the diagnosis of diabetes due to detection/ascertainment bias.

The longitudinal patterns of depression treatment need to be interpreted in the context of changing treatment practices during the study period. The increasing use of antidepressants over the years observed in the present sample reflects the increasing rate of antidepressant prescriptions, which has been documented previously in the general population in Finland (Manderbacka et al. 2011). The decrease in hospitalizations, in turn, reflects a general trend of changing medical practice towards increased ambulatory care of mental disorders (Pirkola & Sohlman, 2005). In line with earlier research suggesting depression to be more common among persons with diabetes in lower SEP (Bell et al. 2005; Engum et al. 2005; Kogan et al. 2009; Dismuke & Egede, 2010; Gary-Webb et al. 2011), low income was in our study associated with higher odds for medicine use and hospitalizations. Differential development was not detected in either of the time trajectories after the diagnosis.

In this study we were able to examine an unselected population of Finnish residents with diabetes. The data for persons with diabetes were collected from comprehensive administrative registers drawing on clinical diagnoses. The data on medicine use were collected from the register of reimbursed prescription medicine costs, and are therefore likely to have good coverage. The data for hospitalizations were collected from the hospital discharge register, the accuracy of which has been assessed to be good (Sund, 2012). For income, we were also able to use individual level register data, which form the base of tax registers, allowing us to avoid both reporting bias and ecological bias. However, our register data did not cover persons with diabetes treated with diet only or undiagnosed cases; therefore our results cover only persons with medically treated diagnosed diabetes. As the registers used do not contain clinical data, we cannot estimate the effect of disease severity on the results. Some of the participants may have been diagnosed with diabetes prior to prescription of medication if they had first been treated with non-pharmaceutical interventions. We were also able to use two indicators of depression care, namely antidepressive medication use and hospitalizations due to depression. The similarity of the results concerning antidepressant medication use and hospitalization for what are likely to be more serious cases of depression, add credibility to our findings.

Our results suggest a net effect of decreased depression treatment after compared to before diabetes diagnosis, supporting the common cause hypothesis rather than the detection/ascertainment bias hypothesis. However, the two hypotheses are not necessarily mutually exclusive, and both mechanisms may be operating at the same time. If this was the case, our results suggest that the effects of common cause are larger than the effects of detection bias, producing a net effect of decreased level of depression treatment.

Conclusions

Our study suggests that the association between diabetes and receiving treatment for depression is unlikely to be explained by the higher detection rate for depression among individuals with diabetes. Instead, the present longitudinal data suggest that individuals diagnosed with diabetes are less likely to be treated for depression over time. This suggests that there may be a common cause between diabetes and depression and that treatment for diabetes may help to prevent future depression among diabetic individuals, although the present data do not provide direct evidence for an underlying biological association between diabetes and depression.

Acknowledgments

This study was partially funded by the Social Insurance Institution (SII), which had no involvement in the design, data collection, findings or decision to publish.

Declaration of Interest

None.

References

- Ali S, Stone MA, Peters JL, Davies MJ, Khunti K (2006). The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. *Diabetic Medicine* 23, 1165–1173.
- Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2001). The prevalence of comorbid depression in adults with diabetes. *Diabetes Care* 24, 1069–1078.

Bell RA, Smith SL, Arcury TA, Snively BM, Stafford JM, Quandt SA (2005). Prevalence and correlates of depressive symptoms among rural older African Americans, Native Americans, and whites with diabetes. *Diabetes Care* 28, 823–829.

de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ (2001). Association of depression and diabetes complications: a meta-analysis. *Psychosomatic Medicine* 63, 619–630.

DiMatteo RM (2004). Variations in patients' adherence to medical recommendations. A quantitative review of 50 years of research. *Medical Care* **42**, 200–209.

Dismuke CE, Egede LE (2010). Association between major depression, depressive symptoms and personal income in US adults with diabetes. *General Hospital Psychiatry* **32**, 484–491.

Edwards R, Burns JA, McElduff P, Young RJ, New JP (2003). Variations in process and outcomes of diabetes care by socio-economic status in Salford, UK. *Diabetologia* 46, 750–759.

Engum A, Mykletun A, Midthjell K, Holen A, Dahl AA (2005). Depression and diabetes: a large population-based study of sociodemographic, lifestyle, and clinical factors associated with depression in type 1 and type 2 diabetes. *Diabetes Care* **28**, 1904–1909.

Gary-Webb TL, Baptiste-Roberts K, Pham L,
Wesche-Thobaben J, Patricio J, Pi-Sunyer FX, Brown AF,
Jones-Corneille L, Brancati FL; the Look AHEAD
Research Group (2011). Neighborhood socioeconomic
status, depression, and health status in the Look AHEAD
(Action for Health in Diabetes) Study. BMC Public Health
11, 349.

Hamer M, Stamatakis E, Kivimaki M, Pascal Kengne A, Batty GD (2010). Psychological distress, glycated hemoglobin, and mortality in adults with and without diabetes. *Psychosomatic Medicine* **72**, 882–886.

Hanninen JA, Takala JK, Keinanen-Kiukaanniemi SM (1999). Depression in subjects with type 2 diabetes. Predictive factors and relation to quality of life. *Diabetes Care* **22**, 997–998.

Harjutsalo V, Sjoberg L, Tuomilehto J (2008). Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. *Lancet* 371, 1777–1782.

Hedeker D, Gibbons RD (1997). Application of random-effects pattern-mixture models for missing data in longitudinal studies. *Psychological Methods* 2, 64–78.

Kivimaki M, Batty GD, Jokela M, Ebmeier KP, Vahtera J, Virtanen M, Brunner EJ, Tabak AG, Witte DR, Kumari M, Singh-Manoux A, Hamer M (2011). Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? *Biological Psychiatry* 70, 978–984.

Kivimaki M, Gunnell D, Lawlor DA, Davey Smith G, Pentti J, Virtanen M, Elovainio M, Klaukka T, Vahtera J (2007). Social inequalities in antidepressant treatment and mortality: a longitudinal register study. *Psychological Medicine* 37, 373–382.

Kivimäki M, Tabák AG, Lawlor DA, Batty GD, Singh-Manoux A, Jokela M, Salo P, Virtanen M, **Oksanen T, Pentti J, Witte DR, Vahtera J** (2010). Antidepressant use before and after diagnosis of diabetes versus diagnosis of cancer. *Diabetes Care* **33**, 1471–1476.

Knol MJ, Geerlings MI, Grobbee DE, Egberts AC, Heerdink ER (2009). Antidepressant use before and after initiation of diabetes mellitus treatment. *Diabetologia* 52, 425–432.

Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F (2006). Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. *Diabetologia* 49, 837–845.

Kogan SM, Brody GH, Chen YF (2009). Depressive symptomatology mediates the effect of socioeconomic disadvantage on HbA(1c) among rural African Americans with type 2 diabetes. *Journal of Psychosomatic Research* **67**, 289–296.

Lammi N, Blomstedt PA, Moltchanova E, Eriksson JG, Tuomilehto J, Karvonen M (2008). Marked temporal increase in the incidence of type 1 and type 2 diabetes among young adults in Finland. *Diabetologia* **51**, 897–899.

Manderbacka K, Sund R, Koski S, Keskimaki I, Elovainio M (2011). Diabetes and depression? Secular trends in the use of antidepressants among persons with diabetes in Finland in 1997–2007. *Pharmacoepidemiology and Drug Safety* **20**, 338–343.

Marcum ZY, Zheng Y, Perera S, Strotmeyer E, Newman AB, Simonsick E, Shor RI, Bauer DC, Donohue JM, Hanlon JT; for the Health ABC Study (2013). Prevalence and correlates of self-reported medication non-adherence among older adults with coronary heart disease, diabetes mellitus and/or hypertension. *Research in Social and Administrative Pharmacy*. Published online: 3 January 2013. doi:10.1016/j. sapharm.2012.12.002.

McWilliams JM, Meara E, Zaslavsky AM, Ayanian JZ (2009). Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of Medicare coverage. *Annals of Internal Medicine* **150**, 505–515.

Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, Pouwer F; European Depression in Diabetes (EDID) Research Consortium (2010). Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. *Diabetologia* 53, 2480–2486.

O'Connor PJ, Crain AL, Rush WA, Hanson AM, Fischer LR, Kluznik JC (2009). Does diabetes double the risk of depression? *Annals of Family Medicine* 7, 328–335.

OECD (2012). What are equivalence scales? (http://www. oecd.org/eco/growth/OECD-Note-EquivalenceScales.pdf). Accessed 20 June 2013.

Onkamo P, Vaananen S, Karvonen M, Tuomilehto J (1999). Worldwide increase in incidence of Type I diabetes – the analysis of the data on published incidence trends. *Diabetologia* **42**, 1395–1403.

1212 K. Manderbacka et al.

- Passa P (2002). Diabetes trends in Europe. *Diabetes/Metabolism Research and Reviews* 18, S3–S8.
- Pirkola S, Sohlman B (2005). Atlas of Mental Health: Statistics from Finland. Stakes: Helsinki (http://www.mhfs.org.uk/ resources/NMHW06/pdf/atlas%20stats%20finland.pdf). Accessed 20 June 2013.
- Sund R (2012). Quality of the Finnish Hospital Discharge Register: a systematic review. *Scandinavian Journal of Public Health* 40, 505–515.
- Sund R, Harno K, Ranta S, Tolppanen E (2010). Evaluation of case inclusion in two population-based diabetes registers. *Finnish Journal of eHealth and eWelfare* 2, 136–146.
- **Sund R, Koski S** (2009). FinDM II. On the register-based measurement of the prevalence and incidence of diabetes and its long-term complications. A technical report.

(www.diabetes.fi/files/1167/DehkoFinDM_Raportti_ENG. pdf). Accessed 27 November 2012.

- Talbot F, Nouwen A (2000). A review of the relationship between depression and diabetes in adults: is there a link? *Diabetes Care* 23, 1556–1562.
- Viinamaki H, Niskanen L, Uusitupa M (1995). Mental well-being in people with non-insulin-dependent diabetes. Acta Psychiatrica Scandinavica 92, 392–397.
- Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G (2007). Socioeconomic disadvantage and primary non-adherence with medication in Sweden. *International Journal for Quality in Health Care* **19**, 134–140.
- Wilf-Miron R, Peled R, Yaari E, Shem-Tov O, Weinner VA, Porath A, Kokia E (2010). Disparities in diabetes care: role of the patient's socio-demographic characteristics. *BMC Public Health* **10**, 729.